{"id":"candida-skin-test-antigen","safety":{"commonSideEffects":[{"rate":null,"effect":"Local induration and erythema at injection site"},{"rate":null,"effect":"Systemic hypersensitivity reactions"}]},"_chembl":null,"_dailymed":{"setId":"4254e4c8-4a44-4766-8caf-61c65dc3267c","title":"CANDIN (CANDIDA ALBICANS SKIN TEST ANTIGEN) INJECTION, SOLUTION [NIELSEN BIOSCIENCES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The antigen is injected intradermally and triggers a Type IV hypersensitivity response in individuals with prior Candida exposure and intact T-cell immunity. The resulting induration at the injection site is measured to evaluate immune competence, particularly in immunocompromised patients or those with suspected immunodeficiency. A positive reaction indicates preserved cell-mediated immunity, while anergy (lack of response) may suggest severe immunosuppression.","oneSentence":"Candida skin test antigen is an intradermal diagnostic agent that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:48:34.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Assessment of cell-mediated immune function in immunocompromised patients"},{"name":"Evaluation of delayed-type hypersensitivity response"}]},"trialDetails":[{"nctId":"NCT05889845","phase":"PHASE3","title":"Candin for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2025-01-22","conditions":"Common Warts (Verruca Vulgaris)","enrollment":330},{"nctId":"NCT05652998","phase":"PHASE4","title":"Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2021-10-15","conditions":"Plane Wart","enrollment":30},{"nctId":"NCT01757392","phase":"PHASE2","title":"Candin Safety & Efficacy Study for the Treatment of Warts","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2012-09","conditions":"Warts, Human Papilloma Virus","enrollment":39},{"nctId":"NCT02393417","phase":"PHASE2","title":"Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2015-03","conditions":"Warts","enrollment":243},{"nctId":"NCT00953927","phase":"PHASE2","title":"A Study of MVA85A in Healthy Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2009-07","conditions":"Tuberculosis","enrollment":2797},{"nctId":"NCT01151189","phase":"PHASE2","title":"Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-07","conditions":"Tuberculosis, HIV Infections","enrollment":650},{"nctId":"NCT00006113","phase":"PHASE2","title":"Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"1999-06","conditions":"Melanoma (Skin)","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Candin(R)","Manufactured by Allermed Laboratories of USA."],"phase":"marketed","status":"active","brandName":"Candida Skin Test Antigen","genericName":"Candida Skin Test Antigen","companyName":"Aeras","companyId":"aeras","modality":"Biologic","firstApprovalDate":"","aiSummary":"Candida skin test antigen is an intradermal diagnostic agent that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function. Used for Assessment of cell-mediated immune function in immunocompromised patients, Evaluation of delayed-type hypersensitivity response.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}